DNCA FINANCE 13D and 13G filings for Evelo Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-21 06:10 am Purchase | 2023-02-21 | 13D | Evelo Biosciences, Inc. EVLO | DNCA FINANCE | 22 4.960% | 22 (New Position) | Filing |
| 2022-11-21 08:28 am Sale | 2022-11-21 | 13D | Evelo Biosciences, Inc. EVLO | DNCA FINANCE | 0 0.000% | -46 (Position Closed) | Filing |
| 2022-08-23 09:32 am Purchase | 2022-08-23 | 13D | Evelo Biosciences, Inc. EVLO | DNCA FINANCE | 46 3.630% | 12 (+33.72%) | Filing |
| 2021-12-28 3:58 pm Purchase | 2021-12-28 | 13D | Evelo Biosciences, Inc. EVLO | DNCA FINANCE | 34 5.030% | 34 (New Position) | Filing |